411 related articles for article (PubMed ID: 28389808)
1. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
Hanamura T; Hayashi SI
Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
[TBL] [Abstract][Full Text] [Related]
2. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
3. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197
[TBL] [Abstract][Full Text] [Related]
5. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma.
Fujii R; Hanamura T; Suzuki T; Gohno T; Shibahara Y; Niwa T; Yamaguchi Y; Ohnuki K; Kakugawa Y; Hirakawa H; Ishida T; Sasano H; Ohuchi N; Hayashi S
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():513-22. PubMed ID: 25178713
[TBL] [Abstract][Full Text] [Related]
6. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869
[TBL] [Abstract][Full Text] [Related]
7. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
8. Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors.
Augusto TV; Amaral C; Varela CL; Bernardo F; da Silva ET; Roleira FFM; Costa S; Teixeira N; Correia-da-Silva G
J Steroid Biochem Mol Biol; 2019 Dec; 195():105486. PubMed ID: 31557516
[TBL] [Abstract][Full Text] [Related]
9. The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.
Sikora MJ; Cordero KE; Larios JM; Johnson MD; Lippman ME; Rae JM
Breast Cancer Res Treat; 2009 May; 115(2):289-96. PubMed ID: 18521740
[TBL] [Abstract][Full Text] [Related]
10. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
[TBL] [Abstract][Full Text] [Related]
11. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy.
Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to aromatase inhibitors: where we stand!
Augusto TV; Correia-da-Silva G; Rodrigues CMP; Teixeira N; Amaral C
Endocr Relat Cancer; 2018 May; 25(5):R283-R301. PubMed ID: 29530940
[TBL] [Abstract][Full Text] [Related]
15. Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
Azariadis K; Kiagiadaki F; Pelekanou V; Bempi V; Alexakis K; Kampa M; Tsapis A; Castanas E; Notas G
Cell Physiol Biochem; 2017; 44(1):66-84. PubMed ID: 29131020
[TBL] [Abstract][Full Text] [Related]
16. Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.
Chan HJ; Petrossian K; Chen S
J Steroid Biochem Mol Biol; 2016 Jul; 161():73-83. PubMed ID: 26277097
[TBL] [Abstract][Full Text] [Related]
17. Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.
Higuchi T; Endo M; Hanamura T; Gohno T; Niwa T; Yamaguchi Y; Horiguchi J; Hayashi S
PLoS One; 2016; 11(5):e0155844. PubMed ID: 27228187
[TBL] [Abstract][Full Text] [Related]
18. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER
Amaral C; Correia-da-Silva G; Almeida CF; Valente MJ; Varela C; Tavares-da-Silva E; Vinggaard AM; Teixeira N; Roleira FMF
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677847
[TBL] [Abstract][Full Text] [Related]
19. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
[TBL] [Abstract][Full Text] [Related]
20. Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy.
Creevey L; Bleach R; Madden SF; Toomey S; Bane FT; Varešlija D; Hill AD; Young LS; McIlroy M
Mol Cancer Ther; 2019 Oct; 18(10):1731-1743. PubMed ID: 31289138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
